PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT PART 03: RESEARCH METHODOLOGY PART 04: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 05: MARKET SIZING • Market definition • Market sizing 2017 • Market size and forecast 2017-2022 PART 06: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 07: MARKET SEGMENTATION BY APPLICATION • Anti-infectives • CNS • Others PART 08: MARKET SEGMENTATION BY CATEGORY • Segmentation by category • Comparison by category • Small molecule generics – Market size and forecast 2017-2022 • Biosimilars – Market size and forecast 2017-2022 • Market opportunity by category PART 09: CUSTOMER LANDSCAPE PART 10: REGIONAL LANDSCAPE • Geographical segmentation • Regional comparison • Americas – Market size and forecast 2017-2022 • APAC – Market size and forecast 2017-2022 • EMEA – Market size and forecast 2017-2022 • Market opportunity PART 11: DECISION FRAMEWORK PART 12: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 13: MARKET TRENDS • Advent of RPA • Rising M&A • Hospital-owned generics PART 14: VENDOR LANDSCAPE • Overview • Landscape disruption PART 15: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • Fresenius Kabi • Mylan • Novartis • Pfizer • Sun Pharmaceutical Industries • Teva Pharmaceutical Industries PART 16: APPENDIX • List of abbreviations   Exhibit 01: Global pharmaceutical market: Market size Exhibit 02: Global pharmaceutical market: Segmentation Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Market definition - Inclusions and exclusions checklist Exhibit 06: Market size 2017 Exhibit 07: Validation techniques employed for market sizing 2017 Exhibit 08: Global generic drugs market – Market size and forecast 2017-2022 ($ bn) Exhibit 09: Global generic drugs market – Year over year growth 2018-2022 (%) Exhibit 10: Five forces analysis 2017 Exhibit 11: Five forces analysis 2022 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 2017 Exhibit 18: Global generic drugs market by category – Market share 2017-2022 (%) Exhibit 19: Comparison by category Exhibit 20: Global generic drugs market by small molecule generics – Market size and forecast 2017-2022 ($ bn) Exhibit 21: Global generic drugs market by small molecule generics – Year over year growth 2018-2022 (%) Exhibit 22: Global generic drugs market by biosimilars – Market size and forecast 2017-2022 ($ bn) Exhibit 23: Global generic drugs market by biosimilars – Year over year growth 2018-2022 (%) Exhibit 24: Market opportunity by category Exhibit 25: Customer landscape Exhibit 26: Global generic drugs market by region – Market share 2017-2022 (%) Exhibit 27: Regional comparison Exhibit 28: Generic drugs market in Americas – Market size and forecast 2017-2022 ($ bn) Exhibit 29: Generic drugs market in Americas – Year over year growth 2018-2022 (%) Exhibit 30: Top three countries in Americas Exhibit 31: Generic drugs market in APAC – Market size and forecast 2017-2022 ($ bn) Exhibit 32: Generic drugs market in APAC – Year over year growth 2018-2022 (%) Exhibit 33: Top three countries in APAC Exhibit 34: Generic drugs market in EMEA – Market size and forecast 2017-2022 ($ bn) Exhibit 35: Generic drugs market in EMEA – Year over year growth 2018-2022 (%) Exhibit 36: Top three countries in EMEA Exhibit 37: Market opportunity Exhibit 38: Exhibit: Drug patent expirations in 2018 Exhibit 39: Vendor landscape Exhibit 40: Landscape disruption Exhibit 41: Vendors covered Exhibit 42: Vendor classification Exhibit 43: Market positioning of vendors Exhibit 44: Fresenius Kabi overview Exhibit 45: Fresenius Kabi – Business segments Exhibit 46: Fresenius Kabi – Organizational developments Exhibit 47: Fresenius Kabi – Geographic focus Exhibit 48: Fresenius Kabi – Segment focus Exhibit 49: Fresenius Kabi – Key offerings Exhibit 50: Mylan overview Exhibit 51: Mylan – Business segments Exhibit 52: Mylan – Organizational developments Exhibit 53: Mylan – Segment focus Exhibit 54: Mylan – Key offerings Exhibit 55: Novartis overview Exhibit 56: Novartis – Business segments Exhibit 57: Novartis – Organizational developments Exhibit 58: Novartis – Geographic focus Exhibit 59: Novartis – Segment focus Exhibit 60: Novartis – Key offerings Exhibit 61: Pfizer overview Exhibit 62: Pfizer – Business segments Exhibit 63: Pfizer – Organizational developments Exhibit 64: Pfizer – Geographic focus Exhibit 65: Pfizer – Segment focus Exhibit 66: Pfizer – Key offerings Exhibit 67: Sun Pharmaceutical Industries overview Exhibit 68: Sun Pharmaceutical Industries – Business segments Exhibit 69: Sun Pharmaceutical Industries – Organizational developments Exhibit 70: Sun Pharmaceutical Industries – Geographic focus Exhibit 71: Sun Pharmaceutical Industries – Segment focus Exhibit 72: Sun Pharmaceutical Industries – Key offerings Exhibit 73: Teva Pharmaceutical Industries overview Exhibit 74: Teva Pharmaceutical Industries – Business segments Exhibit 75: Teva Pharmaceutical Industries – Organizational developments Exhibit 76: Teva Pharmaceutical Industries – Geographic focus Exhibit 77: Teva Pharmaceutical Industries – Segment focus Exhibit 78: Teva Pharmaceutical Industries – Key offerings

Fresenius Kabi Mylan Novartis Pfizer Sun Pharmaceutical Industries Teva Pharmaceutical Industries